#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-12	Recreational	_
1-2	13-16	use	_
1-3	17-19	of	_
1-4	20-23	GHB	_
1-5	24-26	is	_
1-6	27-37	associated	_
1-7	38-42	with	_
1-8	43-54	alterations	_
1-9	55-57	of	_
1-10	58-65	resting	_
1-11	66-71	state	_
1-12	72-82	functional	_
1-13	83-95	connectivity	_
1-14	96-98	of	_
1-15	99-102	the	_
1-16	103-110	central	_
1-17	111-120	executive	_
1-18	121-124	and	_
1-19	125-132	default	_
1-20	133-137	mode	_
1-21	138-146	networks	_
1-22	147-155	Abstract	_
1-23	156-177	Gamma‐hydroxybutyrate	_
1-24	178-182	acid	_
1-25	183-184	(	_
1-26	185-188	GHB	_
1-27	189-190	)	_
1-28	191-193	is	_
1-29	194-195	a	_
1-30	196-208	recreational	_
1-31	209-213	drug	_
1-32	214-218	with	_
1-33	219-220	a	_
1-34	221-225	high	_
1-35	226-235	addictive	_
1-36	236-245	potential	_
1-37	246-247	.	_

2-1	248-254	Severe	_
2-2	255-259	side	_
2-3	260-267	effects	_
2-4	268-272	such	_
2-5	273-275	as	_
2-6	276-287	GHB‐induced	_
2-7	288-292	coma	_
2-8	293-296	are	_
2-9	297-303	common	_
2-10	304-307	and	_
2-11	308-314	linked	_
2-12	315-317	to	_
2-13	318-327	increased	_
2-14	328-337	emergency	_
2-15	338-342	room	_
2-16	343-354	attendances	_
2-17	355-356	.	_

3-1	357-367	Task‐based	_
3-2	368-386	functional‐imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-3	387-394	studies	_
3-4	395-399	have	_
3-5	400-408	revealed	_
3-6	409-411	an	_
3-7	412-423	association	_
3-8	424-431	between	_
3-9	432-435	the	_
3-10	436-443	regular	_
3-11	444-447	use	_
3-12	448-450	of	_
3-13	451-454	GHB	_
3-14	455-458	and	_
3-15	459-467	multiple	_
3-16	468-479	GHB‐induced	_
3-17	480-485	comas	_
3-18	486-487	,	_
3-19	488-491	and	_
3-20	492-499	altered	_
3-21	500-514	neurocognitive	_
3-22	515-523	function	_
3-23	524-525	.	_

4-1	526-533	However	_
4-2	534-537	the	_
4-3	538-545	effects	_
4-4	546-548	of	_
4-5	549-557	multiple	_
4-6	558-569	GHB‐induced	_
4-7	570-575	comas	_
4-8	576-579	and	_
4-9	580-587	regular	_
4-10	588-595	GHB‐use	_
4-11	596-598	on	_
4-12	599-608	intrinsic	_
4-13	609-614	brain	_
4-14	615-627	connectivity	_
4-15	628-634	during	_
4-16	635-639	rest	_
4-17	640-646	remain	_
4-18	647-654	unknown	_
4-19	655-656	.	_

5-1	657-660	The	_
5-2	661-666	study	_
5-3	667-677	population	_
5-4	678-687	consisted	_
5-5	688-690	of	_
5-6	691-693	23	_
5-7	694-703	GHB‐users	_
5-8	704-708	with	_
5-9	709-711	≥4	_
5-10	712-723	GHB‐induced	_
5-11	724-729	comas	_
5-12	730-731	(	_
5-13	732-740	GHB‐Coma	_
5-14	741-742	)	_
5-15	743-744	,	_
5-16	745-747	22	_
5-17	748-757	GHB‐users	_
5-18	758-761	who	_
5-19	762-767	never	_
5-20	768-779	experienced	_
5-21	780-781	a	_
5-22	782-793	GHB‐induced	_
5-23	794-798	coma	_
5-24	799-800	(	_
5-25	801-811	GHB‐NoComa	_
5-26	812-813	)	_
5-27	814-817	and	_
5-28	818-820	24	_
5-29	821-829	polydrug	_
5-30	830-835	users	_
5-31	836-839	who	_
5-32	840-845	never	_
5-33	846-850	used	_
5-34	851-854	GHB	_
5-35	855-856	(	_
5-36	857-863	No‐GHB	_
5-37	864-865	)	_
5-38	866-867	.	_

6-1	868-881	Resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
6-2	882-887	scans	_
6-3	888-892	were	_
6-4	893-902	collected	_
6-5	903-905	to	_
6-6	906-912	assess	_
6-7	913-926	resting‐state	_
6-8	927-950	functional‐connectivity	_
6-9	951-957	within	_
6-10	958-961	and	_
6-11	962-969	between	_
6-12	970-973	the	_
6-13	974-981	default	_
6-14	982-986	mode	_
6-15	987-994	network	_
6-16	995-996	(	_
6-17	997-1000	DMN	_
6-18	1001-1002	)	_
6-19	1003-1004	,	_
6-20	1005-1008	the	_
6-21	1009-1018	bilateral	_
6-22	1019-1026	central	_
6-23	1027-1036	executive	_
6-24	1037-1044	network	_
6-25	1045-1046	(	_
6-26	1047-1050	CEN	_
6-27	1051-1052	)	_
6-28	1053-1056	and	_
6-29	1057-1060	the	_
6-30	1061-1069	salience	_
6-31	1070-1077	network	_
6-32	1078-1079	(	_
6-33	1080-1082	SN	_
6-34	1083-1084	)	_
6-35	1085-1086	.	_

7-1	1087-1090	The	_
7-2	1091-1101	GHB‐NoComa	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-3	1102-1107	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-4	1108-1114	showed	_
7-5	1115-1124	decreased	_
7-6	1125-1129	rsFC	_
7-7	1130-1132	of	_
7-8	1133-1136	the	_
7-9	1137-1142	right	_
7-10	1143-1146	CEN	_
7-11	1147-1151	with	_
7-12	1152-1153	a	_
7-13	1154-1160	region	_
7-14	1161-1163	in	_
7-15	1164-1167	the	_
7-16	1168-1176	anterior	_
7-17	1177-1186	cingulate	_
7-18	1187-1193	cortex	_
7-19	1194-1195	(	_
7-20	1196-1197	p	_
7-21	1198-1201	FWE	_
7-22	1202-1203	=	_
7-23	1204-1209	0.048	_
7-24	1210-1211	)	_
7-25	1212-1215	and	_
7-26	1216-1225	decreased	_
7-27	1226-1230	rsFC	_
7-28	1231-1238	between	_
7-29	1239-1242	the	_
7-30	1243-1248	right	_
7-31	1249-1252	CEN	_
7-32	1253-1256	and	_
7-33	1257-1260	the	_
7-34	1261-1264	DMN	_
7-35	1265-1266	(	_
7-36	1267-1268	p	_
7-37	1269-1272	FWE	_
7-38	1273-1274	=	_
7-39	1275-1280	0.048	_
7-40	1281-1282	)	_
7-41	1283-1287	when	_
7-42	1288-1296	compared	_
7-43	1297-1301	with	_
7-44	1302-1305	the	_
7-45	1306-1312	No‐GHB	_
7-46	1313-1318	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-47	1319-1320	.	_

8-1	1321-1326	These	_
8-2	1327-1334	results	_
8-3	1335-1342	suggest	_
8-4	1343-1347	that	_
8-5	1348-1355	regular	_
8-6	1356-1363	GHB‐use	_
8-7	1364-1366	is	_
8-8	1367-1377	associated	_
8-9	1378-1382	with	_
8-10	1383-1392	decreased	_
8-11	1393-1397	rsFC	_
8-12	1398-1404	within	_
8-13	1405-1408	the	_
8-14	1409-1414	right	_
8-15	1415-1418	CEN	_
8-16	1419-1422	and	_
8-17	1423-1430	between	_
8-18	1431-1434	the	_
8-19	1435-1440	right	_
8-20	1441-1444	CEN	_
8-21	1445-1448	and	_
8-22	1449-1452	the	_
8-23	1453-1456	DMN	_
8-24	1457-1458	.	_

9-1	1459-1462	The	_
9-2	1463-1471	presence	_
9-3	1472-1474	of	_
9-4	1475-1483	multiple	_
9-5	1484-1495	GHB‐induced	_
9-6	1496-1501	comas	_
9-7	1502-1504	is	_
9-8	1505-1508	not	_
9-9	1509-1519	associated	_
9-10	1520-1524	with	_
9-11	1525-1526	(	_
9-12	1527-1537	additional	_
9-13	1538-1539	)	_
9-14	1540-1551	alterations	_
9-15	1552-1554	in	_
9-16	1555-1559	rsFC	_
9-17	1560-1561	.	_

10-1	1562-1571	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1572-1575	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1576-1583	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1584-1596	Participants	_
10-5	1597-1600	For	_
10-6	1601-1605	this	_
10-7	1606-1621	cross‐sectional	_
10-8	1622-1627	study	_
10-9	1628-1629	,	_
10-10	1630-1632	77	_
10-11	1633-1645	participants	_
10-12	1646-1650	were	_
10-13	1651-1660	recruited	_
10-14	1661-1668	through	_
10-15	1669-1678	addiction	_
10-16	1679-1686	centers	_
10-17	1687-1689	in	_
10-18	1690-1693	the	_
10-19	1694-1705	Netherlands	_
10-20	1706-1707	,	_
10-21	1708-1714	flyers	_
10-22	1715-1716	,	_
10-23	1717-1725	internet	_
10-24	1726-1740	advertisements	_
10-25	1741-1742	,	_
10-26	1743-1746	and	_
10-27	1747-1755	snowball	_
10-28	1756-1764	sampling	_
10-29	1765-1766	.	_

11-1	1767-1772	Three	_
11-2	1773-1782	different	_
11-3	1783-1789	groups	_
11-4	1790-1792	of	_
11-5	1793-1805	participants	_
11-6	1806-1813	matched	_
11-7	1814-1816	on	_
11-8	1817-1820	age	_
11-9	1821-1824	and	_
11-10	1825-1834	education	_
11-11	1835-1840	level	_
11-12	1841-1845	were	_
11-13	1846-1854	included	_
11-14	1855-1856	:	_
11-15	1857-1859	23	_
11-16	1860-1869	GHB‐users	_
11-17	1870-1874	with	_
11-18	1875-1877	≥4	_
11-19	1878-1889	GHB‐induced	_
11-20	1890-1895	comas	_
11-21	1896-1897	(	_
11-22	1898-1906	GHB‐Coma	_
11-23	1907-1908	)	_
11-24	1909-1910	;	_
11-25	1911-1913	22	_
11-26	1914-1923	GHB‐users	_
11-27	1924-1931	without	_
11-28	1932-1943	GHB‐induced	_
11-29	1944-1949	comas	_
11-30	1950-1951	(	_
11-31	1952-1962	GHB‐NoComa	_
11-32	1963-1964	)	_
11-33	1965-1966	;	_
11-34	1967-1970	and	_
11-35	1971-1973	24	_
11-36	1974-1982	polydrug	_
11-37	1983-1988	users	_
11-38	1989-1992	who	_
11-39	1993-1998	never	_
11-40	1999-2003	used	_
11-41	2004-2007	GHB	_
11-42	2008-2009	(	_
11-43	2010-2016	No‐GHB	_
11-44	2017-2018	)	_
11-45	2019-2020	.	_

12-1	2021-2030	Inclusion	_
12-2	2031-2039	criteria	_
12-3	2040-2043	for	_
12-4	2044-2047	all	_
12-5	2048-2060	participants	_
12-6	2061-2065	were	_
12-7	2066-2067	:	_
12-8	2068-2071	age	_
12-9	2072-2079	between	_
12-10	2080-2082	18	_
12-11	2083-2086	and	_
12-12	2087-2089	40	_
12-13	2090-2095	years	_
12-14	2096-2097	;	_
12-15	2098-2104	native	_
12-16	2105-2110	Dutch	_
12-17	2111-2118	speaker	_
12-18	2119-2120	;	_
12-19	2121-2125	male	_
12-20	2126-2132	gender	_
12-21	2133-2134	(	_
12-22	2135-2140	since	_
12-23	2141-2144	the	_
12-24	2145-2153	majority	_
12-25	2154-2156	of	_
12-26	2157-2166	GHB‐users	_
12-27	2167-2170	are	_
12-28	2171-2176	males	_
12-29	2177-2178	;	_
12-30	2179-2183	Miró	_
12-31	2184-2186	et	_
12-32	2187-2190	al.	_
12-33	2191-2192	,	_
12-34	2193-2197	2017	_
12-35	2198-2199	)	_
12-36	2200-2201	.	_

13-1	2202-2204	An	_
13-2	2205-2215	additional	_
13-3	2216-2225	inclusion	_
13-4	2226-2235	criterion	_
13-5	2236-2239	for	_
13-6	2240-2249	GHB‐users	_
13-7	2250-2253	was	_
13-8	2254-2257	the	_
13-9	2258-2261	use	_
13-10	2262-2264	of	_
13-11	2265-2268	GHB	_
13-12	2269-2272	≥25	_
13-13	2273-2278	times	_
13-14	2279-2281	in	_
13-15	2282-2285	the	_
13-16	2286-2290	last	_
13-17	2291-2292	2	_
13-18	2293-2298	years	_
13-19	2299-2308	preceding	_
13-20	2309-2313	this	_
13-21	2314-2324	assessment	_
13-22	2325-2326	.	_

14-1	2327-2329	An	_
14-2	2330-2340	additional	_
14-3	2341-2350	inclusion	_
14-4	2351-2360	criterion	_
14-5	2361-2364	for	_
14-6	2365-2368	the	_
14-7	2369-2377	GHB‐Coma	_
14-8	2378-2383	group	_
14-9	2384-2387	was	_
14-10	2388-2389	a	_
14-11	2390-2397	minimum	_
14-12	2398-2400	of	_
14-13	2401-2402	4	_
14-14	2403-2414	GHB‐induced	_
14-15	2415-2420	comas	_
14-16	2421-2423	in	_
14-17	2424-2429	order	_
14-18	2430-2432	to	_
14-19	2433-2441	increase	_
14-20	2442-2445	the	_
14-21	2446-2454	contrast	_
14-22	2455-2459	with	_
14-23	2460-2463	the	_
14-24	2464-2474	GHB‐NoComa	_
14-25	2475-2480	group	_
14-26	2481-2482	.	_

15-1	2483-2491	Polydrug	_
15-2	2492-2495	use	_
15-3	2496-2497	(	_
15-4	2498-2500	or	_
15-5	2501-2507	co‐use	_
15-6	2508-2509	)	_
15-7	2510-2512	of	_
15-8	2513-2518	other	_
15-9	2519-2531	recreational	_
15-10	2532-2537	drugs	_
15-11	2538-2541	was	_
15-12	2542-2549	defined	_
15-13	2550-2552	as	_
15-14	2553-2556	the	_
15-15	2557-2560	use	_
15-16	2561-2563	of	_
15-17	2564-2571	alcohol	_
15-18	2572-2573	,	_
15-19	2574-2582	nicotine	_
15-20	2583-2584	,	_
15-21	2585-2593	cannabis	_
15-22	2594-2595	,	_
15-23	2596-2603	cocaine	_
15-24	2604-2605	,	_
15-25	2606-2609	any	_
15-26	2610-2615	other	_
15-27	2616-2626	stimulants	_
15-28	2627-2628	(	_
15-29	2629-2641	amphetamines	_
15-30	2642-2643	,	_
15-31	2644-2648	khat	_
15-32	2649-2650	,	_
15-33	2651-2666	methylphenidate	_
15-34	2667-2668	)	_
15-35	2669-2670	,	_
15-36	2671-2678	ecstasy	_
15-37	2679-2680	,	_
15-38	2681-2689	ketamine	_
15-39	2690-2691	,	_
15-40	2692-2698	and/or	_
15-41	2699-2708	sedatives	_
15-42	2709-2710	(	_
15-43	2711-2726	benzodiazepines	_
15-44	2727-2728	)	_
15-45	2729-2730	.	_

16-1	2731-2734	The	_
16-2	2735-2744	exclusion	_
16-3	2745-2753	criteria	_
16-4	2754-2757	for	_
16-5	2758-2761	the	_
16-6	2762-2767	study	_
16-7	2768-2772	were	_
16-8	2773-2774	:	_
16-9	2775-2776	a	_
16-10	2777-2784	history	_
16-11	2785-2787	of	_
16-12	2788-2796	epilepsy	_
16-13	2797-2798	,	_
16-14	2799-2806	general	_
16-15	2807-2817	anesthesia	_
16-16	2818-2820	in	_
16-17	2821-2824	the	_
16-18	2825-2826	2	_
16-19	2827-2832	years	_
16-20	2833-2839	before	_
16-21	2840-2843	the	_
16-22	2844-2849	study	_
16-23	2850-2851	;	_
16-24	2852-2853	a	_
16-25	2854-2871	contra‐indication	_
16-26	2872-2875	for	_
16-27	2876-2880	fMRI	_
16-28	2881-2889	scanning	_
16-29	2890-2891	(	_
16-30	2892-2896	e.g.	_
16-31	2897-2898	,	_
16-32	2899-2904	metal	_
16-33	2905-2912	objects	_
16-34	2913-2915	in	_
16-35	2916-2919	the	_
16-36	2920-2924	body	_
16-37	2925-2927	or	_
16-38	2928-2932	head	_
16-39	2933-2939	injury	_
16-40	2940-2941	)	_
16-41	2942-2943	;	_
16-42	2944-2947	any	_
16-43	2948-2952	coma	_
16-44	2953-2962	unrelated	_
16-45	2963-2965	to	_
16-46	2966-2973	GHB‐use	_
16-47	2974-2975	;	_
16-48	2976-2979	and	_
16-49	2980-2989	currently	_
16-50	2990-2995	under	_
16-51	2996-3005	treatment	_
16-52	3006-3009	for	_
16-53	3010-3020	narcolepsy	_
16-54	3021-3025	with	_
16-55	3026-3035	cataplexy	_
16-56	3036-3037	(	_
16-57	3038-3043	since	_
16-58	3044-3053	treatment	_
16-59	3054-3057	may	_
16-60	3058-3065	involve	_
16-61	3066-3069	the	_
16-62	3070-3073	use	_
16-63	3074-3076	of	_
16-64	3077-3087	medication	_
16-65	3088-3093	based	_
16-66	3094-3096	on	_
16-67	3097-3100	GHB	_
16-68	3101-3102	)	_
16-69	3103-3104	.	_

17-1	3105-3110	After	_
17-2	3111-3122	explanation	_
17-3	3123-3125	of	_
17-4	3126-3129	the	_
17-5	3130-3135	study	_
17-6	3136-3145	procedure	_
17-7	3146-3147	,	_
17-8	3148-3155	written	_
17-9	3156-3164	informed	_
17-10	3165-3172	consent	_
17-11	3173-3176	was	_
17-12	3177-3185	obtained	_
17-13	3186-3190	from	_
17-14	3191-3194	all	_
17-15	3195-3207	participants	_
17-16	3208-3213	prior	_
17-17	3214-3216	to	_
17-18	3217-3227	initiation	_
17-19	3228-3230	of	_
17-20	3231-3234	the	_
17-21	3235-3240	study	_
17-22	3241-3242	.	_

18-1	3243-3247	This	_
18-2	3248-3253	study	_
18-3	3254-3257	was	_
18-4	3258-3260	in	_
18-5	3261-3271	accordance	_
18-6	3272-3276	with	_
18-7	3277-3280	the	_
18-8	3281-3289	Helsinki	_
18-9	3290-3301	Declaration	_
18-10	3302-3312	principles	_
18-11	3313-3314	(	_
18-12	3315-3318	7th	_
18-13	3319-3327	revision	_
18-14	3328-3329	,	_
18-15	3330-3334	2013	_
18-16	3335-3336	)	_
18-17	3337-3338	,	_
18-18	3339-3342	the	_
18-19	3343-3350	Medical	_
18-20	3351-3359	Research	_
18-21	3360-3369	Involving	_
18-22	3370-3375	Human	_
18-23	3376-3384	Subjects	_
18-24	3385-3386	(	_
18-25	3387-3390	WMO	_
18-26	3391-3392	,	_
18-27	3393-3397	1998	_
18-28	3398-3399	)	_
18-29	3400-3401	,	_
18-30	3402-3405	and	_
18-31	3406-3414	approved	_
18-32	3415-3417	by	_
18-33	3418-3421	the	_
18-34	3422-3429	Medical	_
18-35	3430-3436	Ethics	_
18-36	3437-3443	Review	_
18-37	3444-3453	Committee	_
18-38	3454-3456	of	_
18-39	3457-3460	the	_
18-40	3461-3469	Academic	_
18-41	3470-3477	Medical	_
18-42	3478-3484	Centre	_
18-43	3485-3486	(	_
18-44	3487-3492	World	_
18-45	3493-3500	Medical	_
18-46	3501-3512	Association	_
18-47	3513-3514	,	_
18-48	3515-3519	2013	_
18-49	3520-3521	)	_
18-50	3522-3523	.	_

19-1	3524-3533	Procedure	_
19-2	3534-3537	The	_
19-3	3538-3542	data	_
19-4	3543-3552	presented	_
19-5	3553-3557	here	_
19-6	3558-3562	were	_
19-7	3563-3567	part	_
19-8	3568-3570	of	_
19-9	3571-3572	a	_
19-10	3573-3579	larger	_
19-11	3580-3585	study	_
19-12	3586-3595	assessing	_
19-13	3596-3599	the	_
19-14	3600-3614	neurocognitive	_
19-15	3615-3618	and	_
19-16	3619-3625	neural	_
19-17	3626-3633	effects	_
19-18	3634-3636	of	_
19-19	3637-3644	regular	_
19-20	3645-3652	GHB‐use	_
19-21	3653-3656	and	_
19-22	3657-3668	GHB‐induced	_
19-23	3669-3674	comas	_
19-24	3675-3677	in	_
19-25	3678-3684	humans	_
19-26	3685-3686	.	_

20-1	3687-3690	The	_
20-2	3691-3696	study	_
20-3	3697-3706	consisted	_
20-4	3707-3709	of	_
20-5	3710-3712	an	_
20-6	3713-3720	initial	_
20-7	3721-3726	urine	_
20-8	3727-3731	test	_
20-9	3732-3733	,	_
20-10	3734-3742	followed	_
20-11	3743-3745	by	_
20-12	3746-3756	completing	_
20-13	3757-3771	questionnaires	_
20-14	3772-3779	related	_
20-15	3780-3782	to	_
20-16	3783-3786	GHB	_
20-17	3787-3790	and	_
20-18	3791-3796	other	_
20-19	3797-3801	drug	_
20-20	3802-3805	use	_
20-21	3806-3807	,	_
20-22	3808-3818	depression	_
20-23	3819-3820	,	_
20-24	3821-3828	anxiety	_
20-25	3829-3830	,	_
20-26	3831-3837	stress	_
20-27	3838-3839	,	_
20-28	3840-3843	and	_
20-29	3844-3855	impulsivity	_
20-30	3856-3862	levels	_
20-31	3863-3864	.	_

21-1	3865-3871	During	_
21-2	3872-3875	the	_
21-3	3876-3886	subsequent	_
21-4	3887-3899	neuroimaging	_
21-5	3900-3907	session	_
21-6	3908-3909	,	_
21-7	3910-3920	structural	_
21-8	3921-3922	,	_
21-9	3923-3926	and	_
21-10	3927-3937	functional	_
21-11	3938-3943	scans	_
21-12	3944-3948	were	_
21-13	3949-3958	collected	_
21-14	3959-3961	in	_
21-15	3962-3965	the	_
21-16	3966-3975	following	_
21-17	3976-3981	order	_
21-18	3982-3983	:	_
21-19	3984-3994	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-20	3995-3998	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-21	3999-4000	;	_
21-22	4001-4014	resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-23	4015-4019	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-24	4020-4021	;	_
21-25	4022-4031	long‐term	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
21-26	4032-4038	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
21-27	4039-4043	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
21-28	4044-4045	;	_
21-29	4046-4055	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
21-30	4056-4064	weighted	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
21-31	4065-4072	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DiffusionWeightedImaging
21-32	4073-4074	,	_
21-33	4075-4089	working‐memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
21-34	4090-4094	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
21-35	4095-4096	;	_
21-36	4097-4104	emotion	_
21-37	4105-4115	processing	_
21-38	4116-4117	.	_

22-1	4118-4125	Finally	_
22-2	4126-4133	outside	_
22-3	4134-4137	the	_
22-4	4138-4145	scanner	_
22-5	4146-4147	,	_
22-6	4148-4160	participants	_
22-7	4161-4170	performed	_
22-8	4171-4180	digitized	_
22-9	4181-4199	neuropsychological	_
22-10	4200-4205	tests	_
22-11	4206-4207	,	_
22-12	4208-4217	including	_
22-13	4218-4224	verbal	_
22-14	4225-4231	memory	_
22-15	4232-4233	,	_
22-16	4234-4241	spatial	_
22-17	4242-4248	memory	_
22-18	4249-4250	,	_
22-19	4251-4262	intra‐extra	_
22-20	4263-4274	dimensional	_
22-21	4275-4278	set	_
22-22	4279-4287	shifting	_
22-23	4288-4289	,	_
22-24	4290-4293	and	_
22-25	4294-4307	probabilistic	_
22-26	4308-4316	reversal	_
22-27	4317-4325	learning	_
22-28	4326-4327	.	_

23-1	4328-4330	In	_
23-2	4331-4335	this	_
23-3	4336-4342	report	_
23-4	4343-4345	we	_
23-5	4346-4350	will	_
23-6	4351-4358	present	_
23-7	4359-4363	data	_
23-8	4364-4371	focused	_
23-9	4372-4374	on	_
23-10	4375-4378	the	_
23-11	4379-4383	rsFC	_
23-12	4384-4392	analysis	_
23-13	4393-4395	of	_
23-14	4396-4400	this	_
23-15	4401-4407	sample	_
23-16	4408-4412	only	_
23-17	4413-4414	.	_

24-1	4415-4420	Other	_
24-2	4421-4425	data	_
24-3	4426-4430	from	_
24-4	4431-4435	this	_
24-5	4436-4441	study	_
24-6	4442-4446	have	_
24-7	4447-4451	been	_
24-8	4452-4461	presented	_
24-9	4462-4471	elsewhere	_
24-10	4472-4473	(	_
24-11	4474-4480	Raposo	_
24-12	4481-4488	Pereira	_
24-13	4489-4491	et	_
24-14	4492-4495	al.	_
24-15	4496-4497	,	_
24-16	4498-4503	2018a	_
24-17	4504-4505	,	_
24-18	4506-4511	2018b	_
24-19	4512-4513	)	_
24-20	4514-4515	.	_

25-1	4516-4529	Questionnaire	_
25-2	4530-4533	and	_
25-3	4534-4543	cognitive	_
25-4	4544-4548	test	_
25-5	4549-4558	Premorbid	_
25-6	4559-4571	intellectual	_
25-7	4572-4583	functioning	_
25-8	4584-4587	was	_
25-9	4588-4596	assessed	_
25-10	4597-4601	with	_
25-11	4602-4605	the	_
25-12	4606-4611	Dutch	_
25-13	4612-4619	version	_
25-14	4620-4622	of	_
25-15	4623-4626	the	_
25-16	4627-4632	Adult	_
25-17	4633-4640	reading	_
25-18	4641-4645	test	_
25-19	4646-4647	,	_
25-20	4648-4650	as	_
25-21	4651-4656	proxy	_
25-22	4657-4660	for	_
25-23	4661-4663	IQ	_
25-24	4664-4665	(	_
25-25	4666-4673	Schmand	_
25-26	4674-4675	,	_
25-27	4676-4682	Bakker	_
25-28	4683-4684	,	_
25-29	4685-4689	Saan	_
25-30	4690-4691	,	_
25-31	4692-4693	&	_
25-32	4694-4700	Louman	_
25-33	4701-4702	,	_
25-34	4703-4707	1991	_
25-35	4708-4709	)	_
25-36	4710-4711	.	_

26-1	4712-4715	The	_
26-2	4716-4720	MATE	_
26-3	4721-4724	2:1	_
26-4	4725-4734	substance	_
26-5	4735-4738	use	_
26-6	4739-4746	section	_
26-7	4747-4750	was	_
26-8	4751-4755	used	_
26-9	4756-4758	to	_
26-10	4759-4765	assess	_
26-11	4766-4769	the	_
26-12	4770-4773	use	_
26-13	4774-4776	of	_
26-14	4777-4786	different	_
26-15	4787-4799	recreational	_
26-16	4800-4805	drugs	_
26-17	4806-4807	(	_
26-18	4808-4817	Schippers	_
26-19	4818-4819	,	_
26-20	4820-4828	Broekman	_
26-21	4829-4830	,	_
26-22	4831-4832	&	_
26-23	4833-4841	Buchholz	_
26-24	4842-4843	,	_
26-25	4844-4848	2011	_
26-26	4849-4850	)	_
26-27	4851-4852	.	_

27-1	4853-4864	Statistical	_
27-2	4865-4873	analysis	_
27-3	4874-4885	Demographic	_
27-4	4886-4889	and	_
27-5	4890-4898	clinical	_
27-6	4899-4903	data	_
27-7	4904-4908	were	_
27-8	4909-4917	analyzed	_
27-9	4918-4922	with	_
27-10	4923-4926	the	_
27-11	4927-4933	SPSS24	_
27-12	4934-4942	software	_
27-13	4943-4944	(	_
27-14	4945-4948	IBM	_
27-15	4949-4957	Software	_
27-16	4958-4967	Analytics	_
27-17	4968-4969	,	_
27-18	4970-4973	New	_
27-19	4974-4978	York	_
27-20	4979-4980	,	_
27-21	4981-4983	NY	_
27-22	4984-4985	)	_
27-23	4986-4987	.	_

28-1	4988-4996	Normally	_
28-2	4997-5008	distributed	_
28-3	5009-5013	data	_
28-4	5014-5018	were	_
28-5	5019-5028	evaluated	_
28-6	5029-5036	through	_
28-7	5037-5045	analysis	_
28-8	5046-5048	of	_
28-9	5049-5057	variance	_
28-10	5058-5059	(	_
28-11	5060-5065	ANOVA	_
28-12	5066-5067	)	_
28-13	5068-5069	.	_

29-1	5070-5072	If	_
29-2	5073-5076	not	_
29-3	5077-5085	normally	_
29-4	5086-5097	distributed	_
29-5	5098-5099	,	_
29-6	5100-5104	data	_
29-7	5105-5108	was	_
29-8	5109-5120	transformed	_
29-9	5121-5123	in	_
29-10	5124-5129	order	_
29-11	5130-5132	to	_
29-12	5133-5139	obtain	_
29-13	5140-5141	a	_
29-14	5142-5148	normal	_
29-15	5149-5161	distribution	_
29-16	5162-5164	or	_
29-17	5165-5174	evaluated	_
29-18	5175-5179	with	_
29-19	5180-5193	nonparametric	_
29-20	5194-5199	tests	_
29-21	5200-5201	)	_
29-22	5202-5203	.	_

30-1	5204-5209	Group	_
30-2	5210-5221	differences	_
30-3	5222-5224	in	_
30-4	5225-5228	GHB	_
30-5	5229-5234	daily	_
30-6	5235-5239	dose	_
30-7	5240-5241	(	_
30-8	5242-5248	mL/day	_
30-9	5249-5250	)	_
30-10	5251-5252	,	_
30-11	5253-5258	years	_
30-12	5259-5264	since	_
30-13	5265-5270	first	_
30-14	5271-5274	use	_
30-15	5275-5276	,	_
30-16	5277-5287	prevalence	_
30-17	5288-5290	of	_
30-18	5291-5295	days	_
30-19	5296-5301	using	_
30-20	5302-5305	GHB	_
30-21	5306-5308	on	_
30-22	5309-5312	the	_
30-23	5313-5321	previous	_
30-24	5322-5327	month	_
30-25	5328-5329	,	_
30-26	5330-5336	months	_
30-27	5337-5339	of	_
30-28	5340-5345	daily	_
30-29	5346-5349	use	_
30-30	5350-5351	,	_
30-31	5352-5355	and	_
30-32	5356-5361	total	_
30-33	5362-5370	exposure	_
30-34	5371-5373	as	_
30-35	5374-5381	defined	_
30-36	5382-5384	by	_
30-37	5385-5390	years	_
30-38	5391-5393	of	_
30-39	5394-5397	use	_
30-40	5398-5399	×	_
30-41	5400-5405	daily	_
30-42	5406-5410	dose	_
30-43	5411-5412	,	_
30-44	5413-5417	were	_
30-45	5418-5424	tested	_
30-46	5425-5427	in	_
30-47	5428-5431	the	_
30-48	5432-5438	groups	_
30-49	5439-5443	that	_
30-50	5444-5448	used	_
30-51	5449-5452	GHB	_
30-52	5453-5454	(	_
30-53	5455-5460	Table	_
30-54	5461-5462	1	_
30-55	5463-5464	)	_
30-56	5465-5466	.	_

31-1	5467-5470	The	_
31-2	5471-5481	assessment	_
31-3	5482-5484	of	_
31-4	5485-5491	co‐use	_
31-5	5492-5494	of	_
31-6	5495-5504	different	_
31-7	5505-5517	recreational	_
31-8	5518-5523	drugs	_
31-9	5524-5527	was	_
31-10	5528-5537	performed	_
31-11	5538-5540	by	_
31-12	5541-5547	asking	_
31-13	5548-5560	participants	_
31-14	5561-5566	about	_
31-15	5567-5570	the	_
31-16	5571-5577	number	_
31-17	5578-5580	of	_
31-18	5581-5585	days	_
31-19	5586-5590	they	_
31-20	5591-5595	used	_
31-21	5596-5597	a	_
31-22	5598-5606	specific	_
31-23	5607-5611	drug	_
31-24	5612-5614	in	_
31-25	5615-5618	the	_
31-26	5619-5628	preceding	_
31-27	5629-5634	month	_
31-28	5635-5636	,	_
31-29	5637-5642	their	_
31-30	5643-5648	usual	_
31-31	5649-5654	daily	_
31-32	5655-5659	dose	_
31-33	5660-5663	and	_
31-34	5664-5667	the	_
31-35	5668-5674	number	_
31-36	5675-5677	of	_
31-37	5678-5683	years	_
31-38	5684-5688	they	_
31-39	5689-5695	weekly	_
31-40	5696-5700	used	_
31-41	5701-5705	each	_
31-42	5706-5710	drug	_
31-43	5711-5712	.	_

32-1	5713-5715	As	_
32-2	5716-5717	a	_
32-3	5718-5724	result	_
32-4	5725-5727	we	_
32-5	5728-5735	defined	_
32-6	5736-5737	a	_
32-7	5738-5743	final	_
32-8	5744-5757	drug‐exposure	_
32-9	5758-5766	variable	_
32-10	5767-5771	that	_
32-11	5772-5775	was	_
32-12	5776-5786	calculated	_
32-13	5787-5789	as	_
32-14	5790-5797	follows	_
32-15	5798-5799	:	_
32-16	5800-5805	years	_
32-17	5806-5808	of	_
32-18	5809-5815	weekly	_
32-19	5816-5819	use	_
32-20	5820-5821	×	_
32-21	5822-5827	daily	_
32-22	5828-5832	dose	_
32-23	5833-5836	for	_
32-24	5837-5841	each	_
32-25	5842-5854	recreational	_
32-26	5855-5859	drug	_
32-27	5860-5870	considered	_
32-28	5871-5873	on	_
32-29	5874-5877	the	_
32-30	5878-5886	MATE:2.1	_
32-31	5887-5900	questionnaire	_
32-32	5901-5902	(	_
32-33	5903-5908	Table	_
32-34	5909-5910	2	_
32-35	5911-5912	)	_
32-36	5913-5914	.	_

33-1	5915-5918	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-2	5919-5923	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-3	5924-5935	acquisition	_
33-4	5936-5939	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-5	5940-5944	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
33-6	5945-5949	were	_
33-7	5950-5959	collected	_
33-8	5960-5964	with	_
33-9	5965-5966	a	_
33-10	5967-5968	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-11	5969-5970	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-12	5971-5978	Ingenia	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-13	5979-5986	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
33-14	5987-5991	with	_
33-15	5992-5993	a	_
33-16	5994-5996	32	_
33-17	5997-6004	channel	_
33-18	6005-6009	head	_
33-19	6010-6014	coil	_
33-20	6015-6016	(	_
33-21	6017-6025	Phillips	_
33-22	6026-6033	Medical	_
33-23	6034-6040	System	_
33-24	6041-6042	,	_
33-25	6043-6047	Best	_
33-26	6048-6049	,	_
33-27	6050-6053	the	_
33-28	6054-6065	Netherlands	_
33-29	6066-6067	)	_
33-30	6068-6069	.	_

34-1	6070-6081	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-2	6082-6092	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-3	6093-6099	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-4	6100-6101	(	_
34-5	6102-6103	[	_
34-6	6104-6112	sagittal	_
34-7	6113-6124	acquisition	_
34-8	6125-6126	;	_
34-9	6127-6132	voxel	_
34-10	6133-6137	size	_
34-11	6138-6139	:	_
34-12	6140-6143	1.0	_
34-13	6144-6145	×	_
34-14	6146-6149	1.0	_
34-15	6150-6151	×	_
34-16	6152-6155	1.0	_
34-17	6156-6159	mm3	_
34-18	6160-6161	;	_
34-19	6162-6166	flip	_
34-20	6167-6172	angle	_
34-21	6173-6174	:	_
34-22	6175-6177	9°	_
34-23	6178-6179	;	_
34-24	6180-6185	field	_
34-25	6186-6188	of	_
34-26	6189-6193	view	_
34-27	6194-6195	[	_
34-28	6196-6199	FOV	_
34-29	6200-6201	]	_
34-30	6202-6203	:	_
34-31	6204-6207	256	_
34-32	6208-6209	×	_
34-33	6210-6213	240	_
34-34	6214-6217	mm2	_
34-35	6218-6219	)	_
34-36	6220-6224	were	_
34-37	6225-6233	acquired	_
34-38	6234-6238	with	_
34-39	6239-6240	a	_
34-40	6241-6254	magnetization	_
34-41	6255-6263	prepared	_
34-42	6264-6269	rapid	_
34-43	6270-6278	gradient	_
34-44	6279-6283	echo	_
34-45	6284-6285	(	_
34-46	6286-6292	MPRAGE	_
34-47	6293-6294	)	_
34-48	6295-6303	sequence	_
34-49	6304-6307	for	_
34-50	6308-6315	spatial	_
34-51	6316-6329	normalization	_
34-52	6330-6338	purposes	_
34-53	6339-6340	.	_

35-1	6341-6343	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-2	6344-6345	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-3	6346-6355	‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-4	6356-6366	functional	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-5	6367-6373	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
35-6	6374-6378	were	_
35-7	6379-6387	acquired	_
35-8	6388-6393	using	_
35-9	6394-6395	a	_
35-10	6396-6399	160	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-11	6400-6411	echo‐planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-12	6412-6419	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-13	6420-6421	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-14	6422-6425	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-15	6426-6427	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-16	6428-6436	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
35-17	6437-6441	with	_
35-18	6442-6444	37	_
35-19	6445-6454	ascending	_
35-20	6455-6461	slices	_
35-21	6462-6463	[	_
35-22	6464-6482	anterior–posterior	_
35-23	6483-6494	acquisition	_
35-24	6495-6496	;	_
35-25	6497-6502	TR/TE	_
35-26	6503-6504	=	_
35-27	6505-6512	2000/27	_
35-28	6513-6515	ms	_
35-29	6516-6517	;	_
35-30	6518-6523	voxel	_
35-31	6524-6528	size	_
35-32	6529-6530	:	_
35-33	6531-6534	3.0	_
35-34	6535-6536	×	_
35-35	6537-6541	3.08	_
35-36	6542-6543	×	_
35-37	6544-6547	3.0	_
35-38	6548-6551	mm3	_
35-39	6552-6553	;	_
35-40	6554-6557	FOV	_
35-41	6558-6559	:	_
35-42	6560-6563	240	_
35-43	6564-6565	×	_
35-44	6566-6569	240	_
35-45	6570-6573	mm2	_
35-46	6574-6575	;	_
35-47	6576-6584	duration	_
35-48	6585-6586	:	_
35-49	6587-6591	5:28	_
35-50	6592-6595	min	_
35-51	6596-6597	]	_
35-52	6598-6599	.	_

36-1	6600-6612	Participants	_
36-2	6613-6617	were	_
36-3	6618-6623	asked	_
36-4	6624-6626	to	_
36-5	6627-6631	keep	_
36-6	6632-6637	their	_
36-7	6638-6642	eyes	_
36-8	6643-6647	open	_
36-9	6648-6649	,	_
36-10	6650-6653	not	_
36-11	6654-6656	to	_
36-12	6657-6662	think	_
36-13	6663-6668	about	_
36-14	6669-6677	anything	_
36-15	6678-6680	in	_
36-16	6681-6691	particular	_
36-17	6692-6693	,	_
36-18	6694-6697	and	_
36-19	6698-6701	not	_
36-20	6702-6704	to	_
36-21	6705-6709	fall	_
36-22	6710-6716	asleep	_
36-23	6717-6718	.	_

37-1	6719-6722	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-2	6723-6736	preprocessing	_
37-3	6737-6749	Neuroimaging	_
37-4	6750-6754	data	_
37-5	6755-6758	was	_
37-6	6759-6767	analyzed	_
37-7	6768-6772	with	_
37-8	6773-6781	Advanced	_
37-9	6782-6795	Normalization	_
37-10	6796-6801	Tools	_
37-11	6802-6803	(	_
37-12	6804-6808	ANTs	_
37-13	6809-6810	;	_
37-14	6811-6815	http	_
37-15	6816-6817	:	_
37-16	6818-6842	//stnava.github.io/ANTs/	_
37-17	6843-6844	)	_
37-18	6845-6853	software	_
37-19	6854-6857	and	_
37-20	6858-6863	FMRIB	_
37-21	6864-6872	Software	_
37-22	6873-6880	Library	_
37-23	6881-6887	5.0.10	_
37-24	6888-6889	(	_
37-25	6890-6893	FSL	_
37-26	6894-6895	;	_
37-27	6896-6904	Analysis	_
37-28	6905-6910	Group	_
37-29	6911-6912	,	_
37-30	6913-6918	FMRIB	_
37-31	6919-6920	,	_
37-32	6921-6927	Oxford	_
37-33	6928-6929	,	_
37-34	6930-6932	UK	_
37-35	6933-6934	;	_
37-36	6935-6939	http	_
37-37	6940-6941	:	_
37-38	6942-6966	//www.fmrib.ox.ac.uk/fsl	_
37-39	6967-6968	;	_
37-40	6969-6975	Avants	_
37-41	6976-6978	et	_
37-42	6979-6982	al.	_
37-43	6983-6984	,	_
37-44	6985-6989	2011	_
37-45	6990-6991	)	_
37-46	6992-6993	.	_

38-1	6994-7007	Preprocessing	_
38-2	7008-7010	of	_
38-3	7011-7023	T1‐weighthed	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-4	7024-7030	images	_
38-5	7031-7034	was	_
38-6	7035-7044	performed	_
38-7	7045-7047	in	_
38-8	7048-7051	the	_
38-9	7052-7061	following	_
38-10	7062-7067	order	_
38-11	7068-7069	:	_
38-12	7070-7071	(	_
38-13	7072-7073	a	_
38-14	7074-7075	)	_
38-15	7076-7086	bias‐field	_
38-16	7087-7097	correction	_
38-17	7098-7103	using	_
38-18	7104-7107	the	_
38-19	7108-7120	N4‐algorithm	_
38-20	7121-7122	;	_
38-21	7123-7124	(	_
38-22	7125-7126	b	_
38-23	7127-7128	)	_
38-24	7129-7141	registration	_
38-25	7142-7147	based	_
38-26	7148-7164	brain‐extraction	_
38-27	7165-7170	using	_
38-28	7171-7174	the	_
38-29	7175-7180	OASIS	_
38-30	7181-7186	atlas	_
38-31	7187-7195	template	_
38-32	7196-7197	;	_
38-33	7198-7199	(	_
38-34	7200-7201	c	_
38-35	7202-7203	)	_
38-36	7204-7216	segmentation	_
38-37	7217-7221	into	_
38-38	7222-7226	gray	_
38-39	7227-7233	matter	_
38-40	7234-7235	(	_
38-41	7236-7238	GM	_
38-42	7239-7240	;	_
38-43	7241-7243	GM	_
38-44	7244-7248	maps	_
38-45	7249-7253	were	_
38-46	7254-7258	used	_
38-47	7259-7261	as	_
38-48	7262-7272	voxel‐wise	_
38-49	7273-7283	covariates	_
38-50	7284-7290	during	_
38-51	7291-7294	the	_
38-52	7295-7303	analysis	_
38-53	7304-7305	)	_
38-54	7306-7307	,	_
38-55	7308-7313	white	_
38-56	7314-7320	matter	_
38-57	7321-7322	(	_
38-58	7323-7325	WM	_
38-59	7326-7327	)	_
38-60	7328-7329	,	_
38-61	7330-7333	and	_
38-62	7334-7347	cerebrospinal	_
38-63	7348-7353	fluid	_
38-64	7354-7355	(	_
38-65	7356-7359	CSF	_
38-66	7360-7361	)	_
38-67	7362-7369	partial	_
38-68	7370-7376	volume	_
38-69	7377-7386	estimates	_
38-70	7387-7392	using	_
38-71	7393-7396	FSL	_
38-72	7397-7399	's	_
38-73	7400-7404	FAST	_
38-74	7405-7409	tool	_
38-75	7410-7411	;	_
38-76	7412-7415	and	_
38-77	7416-7417	(	_
38-78	7418-7419	d	_
38-79	7420-7421	)	_
38-80	7422-7434	registration	_
38-81	7435-7439	into	_
38-82	7440-7446	MNI152	_
38-83	7447-7452	space	_
38-84	7453-7458	using	_
38-85	7459-7463	ANTs	_
38-86	7464-7465	'	_
38-87	7466-7475	symmetric	_
38-88	7476-7489	normalization	_
38-89	7490-7499	algorithm	_
38-90	7500-7501	(	_
38-91	7502-7508	Avants	_
38-92	7509-7511	et	_
38-93	7512-7515	al.	_
38-94	7516-7517	,	_
38-95	7518-7522	2011	_
38-96	7523-7524	;	_
38-97	7525-7531	Marcus	_
38-98	7532-7534	et	_
38-99	7535-7538	al.	_
38-100	7539-7540	,	_
38-101	7541-7545	2007	_
38-102	7546-7547	;	_
38-103	7548-7556	Tustison	_
38-104	7557-7559	et	_
38-105	7560-7563	al.	_
38-106	7564-7565	,	_
38-107	7566-7570	2010	_
38-108	7571-7572	)	_
38-109	7573-7574	.	_

39-1	7575-7588	Preprocessing	_
39-2	7589-7591	of	_
39-3	7592-7594	T2	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
39-4	7595-7596	*	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
39-5	7597-7607	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
39-6	7608-7614	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
39-7	7615-7624	consisted	_
39-8	7625-7627	of	_
39-9	7628-7629	:	_
39-10	7630-7641	realignment	_
39-11	7642-7647	using	_
39-12	7648-7655	MCFLIRT	_
39-13	7656-7657	;	_
39-14	7658-7673	co‐registration	_
39-15	7674-7676	to	_
39-16	7677-7688	T1‐weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-17	7689-7695	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
39-18	7696-7701	using	_
39-19	7702-7705	the	_
39-20	7706-7720	boundary‐based	_
39-21	7721-7733	registration	_
39-22	7734-7743	algorithm	_
39-23	7744-7745	;	_
39-24	7746-7753	spatial	_
39-25	7754-7763	smoothing	_
39-26	7764-7768	with	_
39-27	7769-7770	a	_
39-28	7771-7772	6	_
39-29	7773-7775	mm	_
39-30	7776-7780	FWHM	_
39-31	7781-7789	Gaussian	_
39-32	7790-7796	kernel	_
39-33	7797-7798	(	_
39-34	7799-7804	Greve	_
39-35	7805-7806	&	_
39-36	7807-7813	Fischl	_
39-37	7814-7815	,	_
39-38	7816-7820	2009	_
39-39	7821-7822	)	_
39-40	7823-7824	.	_

40-1	7825-7828	The	_
40-2	7829-7836	general	_
40-3	7837-7842	level	_
40-4	7843-7845	of	_
40-5	7846-7852	motion	_
40-6	7853-7855	in	_
40-7	7856-7861	these	_
40-8	7862-7867	scans	_
40-9	7868-7871	was	_
40-10	7872-7880	assessed	_
40-11	7881-7885	with	_
40-12	7886-7896	frame‐wise	_
40-13	7897-7909	displacement	_
40-14	7910-7919	estimates	_
40-15	7920-7921	(	_
40-16	7922-7924	FD	_
40-17	7925-7926	;	_
40-18	7927-7936	Jenkinson	_
40-19	7937-7938	,	_
40-20	7939-7948	Bannister	_
40-21	7949-7950	,	_
40-22	7951-7956	Brady	_
40-23	7957-7958	,	_
40-24	7959-7960	&	_
40-25	7961-7966	Smith	_
40-26	7967-7968	,	_
40-27	7969-7973	2002	_
40-28	7974-7975	;	_
40-29	7976-7985	Jenkinson	_
40-30	7986-7987	,	_
40-31	7988-7996	Beckmann	_
40-32	7997-7998	,	_
40-33	7999-8006	Behrens	_
40-34	8007-8008	,	_
40-35	8009-8017	Woolrich	_
40-36	8018-8019	,	_
40-37	8020-8021	&	_
40-38	8022-8027	Smith	_
40-39	8028-8029	,	_
40-40	8030-8034	2012	_
40-41	8035-8036	)	_
40-42	8037-8038	.	_

41-1	8039-8050	High‐motion	_
41-2	8051-8059	subjects	_
41-3	8060-8064	were	_
41-4	8065-8073	excluded	_
41-5	8074-8079	based	_
41-6	8080-8082	on	_
41-7	8083-8086	the	_
41-8	8087-8096	following	_
41-9	8097-8105	criteria	_
41-10	8106-8107	:	_
41-11	8108-8109	(	_
41-12	8110-8111	a	_
41-13	8112-8113	)	_
41-14	8114-8116	if	_
41-15	8117-8120	any	_
41-16	8121-8132	translation	_
41-17	8133-8135	or	_
41-18	8136-8144	rotation	_
41-19	8145-8155	parameters	_
41-20	8156-8164	exceeded	_
41-21	8165-8166	4	_
41-22	8167-8176	mm/degree	_
41-23	8177-8178	;	_
41-24	8179-8180	(	_
41-25	8181-8182	b	_
41-26	8183-8184	)	_
41-27	8185-8187	if	_
41-28	8188-8191	the	_
41-29	8192-8199	average	_
41-30	8200-8202	FD	_
41-31	8203-8206	was	_
41-32	8207-8208	>	_
41-33	8209-8212	0.3	_
41-34	8213-8215	mm	_
41-35	8216-8217	;	_
41-36	8218-8219	(	_
41-37	8220-8221	c	_
41-38	8222-8223	)	_
41-39	8224-8226	if	_
41-40	8227-8231	more	_
41-41	8232-8236	than	_
41-42	8237-8239	40	_
41-43	8240-8247	volumes	_
41-44	8248-8251	had	_
41-45	8252-8254	an	_
41-46	8255-8265	individual	_
41-47	8266-8268	FD	_
41-48	8269-8274	value	_
41-49	8275-8276	>	_
41-50	8277-8281	0.25	_
41-51	8282-8284	mm	_
41-52	8285-8292	leading	_
41-53	8293-8295	to	_
41-54	8296-8297	<	_
41-55	8298-8299	4	_
41-56	8300-8303	min	_
41-57	8304-8306	of	_
41-58	8307-8313	motion	_
41-59	8314-8324	unaffected	_
41-60	8325-8338	resting‐state	_
41-61	8339-8343	data	_
41-62	8344-8347	for	_
41-63	8348-8351	the	_
41-64	8352-8360	analysis	_
41-65	8361-8362	;	_
41-66	8363-8364	(	_
41-67	8365-8366	d	_
41-68	8367-8368	)	_
41-69	8369-8376	partial	_
41-70	8377-8382	field	_
41-71	8383-8385	of	_
41-72	8386-8390	view	_
41-73	8391-8397	during	_
41-74	8398-8406	scanning	_
41-75	8407-8408	(	_
41-76	8409-8422	Satterthwaite	_
41-77	8423-8425	et	_
41-78	8426-8429	al.	_
41-79	8430-8431	,	_
41-80	8432-8436	2013	_
41-81	8437-8438	;	_
41-82	8439-8442	van	_
41-83	8443-8447	Dijk	_
41-84	8448-8449	,	_
41-85	8450-8457	Sabuncu	_
41-86	8458-8459	,	_
41-87	8460-8461	&	_
41-88	8462-8469	Buckner	_
41-89	8470-8471	,	_
41-90	8472-8476	2012	_
41-91	8477-8478	)	_
41-92	8479-8480	.	_

42-1	8481-8486	Based	_
42-2	8487-8489	on	_
42-3	8490-8495	these	_
42-4	8496-8504	criteria	_
42-5	8505-8508	two	_
42-6	8509-8521	participants	_
42-7	8522-8526	from	_
42-8	8527-8530	the	_
42-9	8531-8539	GHB‐Coma	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
42-10	8540-8545	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
42-11	8546-8547	,	_
42-12	8548-8553	three	_
42-13	8554-8565	participant	_
42-14	8566-8570	from	_
42-15	8571-8574	the	_
42-16	8575-8585	GHB‐NoComa	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
42-17	8586-8591	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
42-18	8592-8593	,	_
42-19	8594-8597	and	_
42-20	8598-8603	three	_
42-21	8604-8616	participants	_
42-22	8617-8621	from	_
42-23	8622-8625	the	_
42-24	8626-8632	No‐GHB	_
42-25	8633-8638	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
42-26	8639-8643	were	_
42-27	8644-8652	excluded	_
42-28	8653-8654	.	_

43-1	8655-8658	The	_
43-2	8659-8668	remaining	_
43-3	8669-8681	participants	_
43-4	8682-8685	did	_
43-5	8686-8689	not	_
43-6	8690-8694	show	_
43-7	8695-8698	any	_
43-8	8699-8704	group	_
43-9	8705-8716	differences	_
43-10	8717-8719	on	_
43-11	8720-8727	average	_
43-12	8728-8730	FD	_
43-13	8731-8732	(	_
43-14	8733-8734	F	_
43-15	8735-8736	(	_
43-16	8737-8741	2,66	_
43-17	8742-8743	)	_
43-18	8744-8745	=	_
43-19	8746-8751	1.822	_
43-20	8752-8753	;	_
43-21	8754-8755	p	_
43-22	8756-8757	=	_
43-23	8758-8763	0.170	_
43-24	8764-8765	;	_
43-25	8766-8771	Table	_
43-26	8772-8773	1	_
43-27	8774-8775	)	_
43-28	8776-8777	.	_

44-1	8778-8780	As	_
44-2	8781-8790	remaining	_
44-3	8791-8797	motion	_
44-4	8798-8801	can	_
44-5	8802-8807	still	_
44-6	8808-8815	exhibit	_
44-7	8816-8817	a	_
44-8	8818-8824	strong	_
44-9	8825-8831	effect	_
44-10	8832-8834	on	_
44-11	8835-8848	resting‐state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-12	8849-8853	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
44-13	8854-8858	data	_
44-14	8859-8860	,	_
44-15	8861-8871	additional	_
44-16	8872-8878	motion	_
44-17	8879-8888	denoising	_
44-18	8889-8892	was	_
44-19	8893-8902	performed	_
44-20	8903-8908	using	_
44-21	8909-8918	ICA‐AROMA	_
44-22	8919-8920	(	_
44-23	8921-8926	Ciric	_
44-24	8927-8929	et	_
44-25	8930-8933	al.	_
44-26	8934-8935	,	_
44-27	8936-8940	2017	_
44-28	8941-8942	;	_
44-29	8943-8949	Parkes	_
44-30	8950-8951	,	_
44-31	8952-8959	Fulcher	_
44-32	8960-8961	,	_
44-33	8962-8967	Yücel	_
44-34	8968-8969	,	_
44-35	8970-8971	&	_
44-36	8972-8979	Fornito	_
44-37	8980-8981	,	_
44-38	8982-8986	2018	_
44-39	8987-8988	)	_
44-40	8989-8990	.	_

45-1	8991-9000	ICA‐AROMA	_
45-2	9001-9014	automatically	_
45-3	9015-9025	identifies	_
45-4	9026-9032	motion	_
45-5	9033-9043	components	_
45-6	9044-9046	of	_
45-7	9047-9061	single‐subject	_
45-8	9062-9065	ICA	_
45-9	9066-9069	and	_
45-10	9070-9077	removes	_
45-11	9078-9082	them	_
45-12	9083-9087	from	_
45-13	9088-9092	each	_
45-14	9093-9104	participant	_
45-15	9105-9107	's	_
45-16	9108-9118	functional	_
45-17	9119-9123	data	_
45-18	9124-9125	(	_
45-19	9126-9131	Pruim	_
45-20	9132-9134	et	_
45-21	9135-9138	al.	_
45-22	9139-9140	,	_
45-23	9141-9145	2015	_
45-24	9146-9147	;	_
45-25	9148-9153	Pruim	_
45-26	9154-9155	,	_
45-27	9156-9162	Mennes	_
45-28	9163-9164	,	_
45-29	9165-9174	Buitelaar	_
45-30	9175-9176	,	_
45-31	9177-9178	&	_
45-32	9179-9187	Beckmann	_
45-33	9188-9189	,	_
45-34	9190-9194	2015	_
45-35	9195-9196	)	_
45-36	9197-9198	.	_

46-1	9199-9201	To	_
46-2	9202-9209	address	_
46-3	9210-9220	additional	_
46-4	9221-9231	structured	_
46-5	9232-9237	noise	_
46-6	9238-9245	present	_
46-7	9246-9248	in	_
46-8	9249-9252	the	_
46-9	9253-9257	data	_
46-10	9258-9259	,	_
46-11	9260-9263	the	_
46-12	9264-9268	mean	_
46-13	9269-9272	CSF	_
46-14	9273-9276	and	_
46-15	9277-9279	WM	_
46-16	9280-9286	signal	_
46-17	9287-9290	was	_
46-18	9291-9300	regressed	_
46-19	9301-9304	out	_
46-20	9305-9307	of	_
46-21	9308-9311	the	_
46-22	9312-9322	functional	_
46-23	9323-9329	images	_
46-24	9330-9332	by	_
46-25	9333-9345	transforming	_
46-26	9346-9349	the	_
46-27	9350-9356	WM/CSF	_
46-28	9357-9370	segmentations	_
46-29	9371-9379	obtained	_
46-30	9380-9384	from	_
46-31	9385-9388	the	_
46-32	9389-9391	T1	_
46-33	9392-9397	image	_
46-34	9398-9400	to	_
46-35	9401-9404	EPI	_
46-36	9405-9410	space	_
46-37	9411-9412	.	_

47-1	9413-9425	Subsequently	_
47-2	9426-9427	,	_
47-3	9428-9433	these	_
47-4	9434-9440	images	_
47-5	9441-9445	were	_
47-6	9446-9460	conservatively	_
47-7	9461-9472	thresholded	_
47-8	9473-9475	at	_
47-9	9476-9478	99	_
47-10	9479-9480	%	_
47-11	9481-9482	,	_
47-12	9483-9489	eroded	_
47-13	9490-9494	once	_
47-14	9495-9496	,	_
47-15	9497-9500	and	_
47-16	9501-9505	used	_
47-17	9506-9509	for	_
47-18	9510-9521	calculating	_
47-19	9522-9525	the	_
47-20	9526-9530	mean	_
47-21	9531-9537	signal	_
47-22	9538-9544	within	_
47-23	9545-9549	each	_
47-24	9550-9552	of	_
47-25	9553-9556	the	_
47-26	9557-9562	masks	_
47-27	9563-9564	.	_

48-1	9565-9568	The	_
48-2	9569-9576	cleaned	_
48-3	9577-9587	functional	_
48-4	9588-9594	images	_
48-5	9595-9599	were	_
48-6	9600-9604	then	_
48-7	9605-9614	high‐pass	_
48-8	9615-9623	filtered	_
48-9	9624-9628	with	_
48-10	9629-9630	a	_
48-11	9631-9638	cut‐off	_
48-12	9639-9641	of	_
48-13	9642-9645	100	_
48-14	9646-9647	s	_
48-15	9648-9651	and	_
48-16	9652-9663	transformed	_
48-17	9664-9668	into	_
48-18	9669-9675	MNI152	_
48-19	9676-9681	space	_
48-20	9682-9684	at	_
48-21	9685-9686	4	_
48-22	9687-9690	mm3	_
48-23	9691-9692	.	_

49-1	9693-9697	fMRI	_
49-2	9698-9706	analysis	_
49-3	9707-9711	RSNs	_
49-4	9712-9716	were	_
49-5	9717-9726	estimated	_
49-6	9727-9732	using	_
49-7	9733-9736	the	_
49-8	9737-9744	MELODIC	_
49-9	9745-9753	software	_
49-10	9754-9765	implemented	_
49-11	9766-9768	in	_
49-12	9769-9772	FSL	_
49-13	9773-9775	by	_
49-14	9776-9786	performing	_
49-15	9787-9790	ICA	_
49-16	9791-9793	on	_
49-17	9794-9797	the	_
49-18	9798-9808	temporally	_
49-19	9809-9821	concatenated	_
49-20	9822-9826	fMRI	_
49-21	9827-9831	data	_
49-22	9832-9833	(	_
49-23	9834-9843	group‐ICA	_
49-24	9844-9845	;	_
49-25	9846-9854	Beckmann	_
49-26	9855-9856	,	_
49-27	9857-9863	DeLuca	_
49-28	9864-9865	,	_
49-29	9866-9872	Devlin	_
49-30	9873-9874	,	_
49-31	9875-9876	&	_
49-32	9877-9882	Smith	_
49-33	9883-9884	,	_
49-34	9885-9889	2005	_
49-35	9890-9891	)	_
49-36	9892-9893	.	_

50-1	9894-9896	In	_
50-2	9897-9902	order	_
50-3	9903-9905	to	_
50-4	9906-9913	produce	_
50-5	9914-9918	more	_
50-6	9919-9925	stable	_
50-7	9926-9928	RS	_
50-8	9929-9939	components	_
50-9	9940-9941	a	_
50-10	9942-9950	meta‐ICA	_
50-11	9951-9959	approach	_
50-12	9960-9963	was	_
50-13	9964-9968	used	_
50-14	9969-9970	(	_
50-15	9971-9977	Biswal	_
50-16	9978-9980	et	_
50-17	9981-9984	al.	_
50-18	9985-9986	,	_
50-19	9987-9991	2010	_
50-20	9992-9993	;	_
50-21	9994-10002	Cerliani	_
50-22	10003-10005	et	_
50-23	10006-10009	al.	_
50-24	10010-10011	,	_
50-25	10012-10016	2015	_
50-26	10017-10018	;	_
50-27	10019-10024	Poppe	_
50-28	10025-10027	et	_
50-29	10028-10031	al.	_
50-30	10032-10033	,	_
50-31	10034-10038	2013	_
50-32	10039-10040	;	_
50-33	10041-10046	Smith	_
50-34	10047-10049	et	_
50-35	10050-10053	al.	_
50-36	10054-10055	,	_
50-37	10056-10060	2009	_
50-38	10061-10062	)	_
50-39	10063-10064	.	_

51-1	10065-10068	For	_
51-2	10069-10073	this	_
51-3	10074-10075	,	_
51-4	10076-10078	an	_
51-5	10079-10090	independent	_
51-6	10091-10101	randomized	_
51-7	10102-10108	subset	_
51-8	10109-10111	of	_
51-9	10112-10114	10	_
51-10	10115-10127	participants	_
51-11	10128-10131	per	_
51-12	10132-10137	group	_
51-13	10138-10142	from	_
51-14	10143-10145	an	_
51-15	10146-10154	eligible	_
51-16	10155-10161	sample	_
51-17	10162-10164	of	_
51-18	10165-10167	69	_
51-19	10168-10179	individuals	_
51-20	10180-10183	was	_
51-21	10184-10193	extracted	_
51-22	10194-10196	25	_
51-23	10197-10202	times	_
51-24	10203-10204	,	_
51-25	10205-10208	and	_
51-26	10209-10219	group‐ICAs	_
51-27	10220-10224	were	_
51-28	10225-10234	performed	_
51-29	10235-10238	for	_
51-30	10239-10243	each	_
51-31	10244-10246	of	_
51-32	10247-10252	those	_
51-33	10253-10254	.	_

52-1	10255-10267	Subsequently	_
52-2	10268-10269	,	_
52-3	10270-10271	a	_
52-4	10272-10280	meta‐ICA	_
52-5	10281-10284	was	_
52-6	10285-10294	performed	_
52-7	10295-10297	on	_
52-8	10298-10301	the	_
52-9	10302-10314	concatenated	_
52-10	10315-10322	spatial	_
52-11	10323-10333	components	_
52-12	10334-10338	from	_
52-13	10339-10342	all	_
52-14	10343-10349	single	_
52-15	10350-10353	ICA	_
52-16	10354-10358	runs	_
52-17	10359-10360	.	_

53-1	10361-10367	Twenty	_
53-2	10368-10378	dimensions	_
53-3	10379-10383	were	_
53-4	10384-10388	used	_
53-5	10389-10393	both	_
53-6	10394-10397	for	_
53-7	10398-10401	the	_
53-8	10402-10408	single	_
53-9	10409-10412	and	_
53-10	10413-10421	meta‐ICA	_
53-11	10422-10424	to	_
53-12	10425-10431	obtain	_
53-13	10432-10433	a	_
53-14	10434-10449	low‐dimensional	_
53-15	10450-10464	representation	_
53-16	10465-10467	of	_
53-17	10468-10471	the	_
53-18	10472-10476	data	_
53-19	10477-10482	which	_
53-20	10483-10488	makes	_
53-21	10489-10491	it	_
53-22	10492-10502	comparable	_
53-23	10503-10505	to	_
53-24	10506-10509	the	_
53-25	10510-10520	literature	_
53-26	10521-10522	(	_
53-27	10523-10529	Biswal	_
53-28	10530-10532	et	_
53-29	10533-10536	al.	_
53-30	10537-10538	,	_
53-31	10539-10543	2010	_
53-32	10544-10545	;	_
53-33	10546-10551	Smith	_
53-34	10552-10554	et	_
53-35	10555-10558	al.	_
53-36	10559-10560	,	_
53-37	10561-10565	2009	_
53-38	10566-10567	)	_
53-39	10568-10569	.	_

54-1	10570-10573	The	_
54-2	10574-10576	20	_
54-3	10577-10585	obtained	_
54-4	10586-10597	independent	_
54-5	10598-10608	components	_
54-6	10609-10613	were	_
54-7	10614-10622	visually	_
54-8	10623-10630	checked	_
54-9	10631-10634	and	_
54-10	10635-10643	compared	_
54-11	10644-10648	with	_
54-12	10649-10659	well‐known	_
54-13	10660-10663	RSN	_
54-14	10664-10673	templates	_
54-15	10674-10678	from	_
54-16	10679-10682	the	_
54-17	10683-10693	literature	_
54-18	10694-10695	.	_

55-1	10696-10700	From	_
55-2	10701-10706	these	_
55-3	10707-10708	,	_
55-4	10709-10711	19	_
55-5	10712-10715	ICs	_
55-6	10716-10720	were	_
55-7	10721-10731	identified	_
55-8	10732-10734	as	_
55-9	10735-10746	established	_
55-10	10747-10751	RSNs	_
55-11	10752-10756	from	_
55-12	10757-10762	which	_
55-13	10763-10767	four	_
55-14	10768-10769	,	_
55-15	10770-10776	namely	_
55-16	10777-10780	the	_
55-17	10781-10786	right	_
55-18	10787-10790	CEN	_
55-19	10791-10792	(	_
55-20	10793-10798	R‐CEN	_
55-21	10799-10800	)	_
55-22	10801-10802	,	_
55-23	10803-10807	left	_
55-24	10808-10811	CEN	_
55-25	10812-10813	(	_
55-26	10814-10819	L‐CEN	_
55-27	10820-10821	)	_
55-28	10822-10823	,	_
55-29	10824-10826	SN	_
55-30	10827-10828	,	_
55-31	10829-10832	and	_
55-32	10833-10836	DMN	_
55-33	10837-10841	were	_
55-34	10842-10850	selected	_
55-35	10851-10853	as	_
55-36	10854-10857	the	_
55-37	10858-10862	RSNs	_
55-38	10863-10865	of	_
55-39	10866-10874	interest	_
55-40	10875-10878	for	_
55-41	10879-10886	further	_
55-42	10887-10895	analysis	_
55-43	10896-10897	(	_
55-44	10898-10904	Figure	_
55-45	10905-10906	1	_
55-46	10907-10908	;	_
55-47	10909-10919	Supporting	_
55-48	10920-10931	Information	_
55-49	10932-10938	Figure	_
55-50	10939-10941	S1	_
55-51	10942-10943	;	_
55-52	10944-10950	Biswal	_
55-53	10951-10953	et	_
55-54	10954-10957	al.	_
55-55	10958-10959	,	_
55-56	10960-10964	2010	_
55-57	10965-10966	;	_
55-58	10967-10972	Laird	_
55-59	10973-10975	et	_
55-60	10976-10979	al.	_
55-61	10980-10981	,	_
55-62	10982-10986	2011	_
55-63	10987-10988	;	_
55-64	10989-10994	Smith	_
55-65	10995-10997	et	_
55-66	10998-11001	al.	_
55-67	11002-11003	,	_
55-68	11004-11008	2009	_
55-69	11009-11010	)	_
55-70	11011-11012	.	_

56-1	11013-11015	To	_
56-2	11016-11022	verify	_
56-3	11023-11030	whether	_
56-4	11031-11034	the	_
56-5	11035-11041	target	_
56-6	11042-11050	networks	_
56-7	11051-11063	corresponded	_
56-8	11064-11066	to	_
56-9	11067-11070	our	_
56-10	11071-11079	networks	_
56-11	11080-11082	of	_
56-12	11083-11091	interest	_
56-13	11092-11094	we	_
56-14	11095-11104	spatially	_
56-15	11105-11115	correlated	_
56-16	11116-11119	our	_
56-17	11120-11122	20	_
56-18	11123-11134	independent	_
56-19	11135-11145	components	_
56-20	11146-11150	with	_
56-21	11151-11154	the	_
56-22	11155-11157	20	_
56-23	11158-11168	components	_
56-24	11169-11177	provided	_
56-25	11178-11180	by	_
56-26	11181-11186	Smith	_
56-27	11187-11189	et	_
56-28	11190-11192	al	_
56-29	11193-11194	.	_

57-1	11195-11196	(	_
57-2	11197-11201	2009	_
57-3	11202-11203	)	_
57-4	11204-11209	using	_
57-5	11210-11213	the	_
57-6	11214-11215	“	_
57-7	11216-11221	fslcc	_
57-8	11222-11223	”	_
57-9	11224-11228	tool	_
57-10	11229-11233	from	_
57-11	11234-11237	FSL	_
57-12	11238-11239	(	_
57-13	11240-11245	Smith	_
57-14	11246-11248	et	_
57-15	11249-11252	al.	_
57-16	11253-11254	,	_
57-17	11255-11259	2009	_
57-18	11260-11261	)	_
57-19	11262-11263	.	_

58-1	11264-11267	The	_
58-2	11268-11272	four	_
58-3	11273-11281	networks	_
58-4	11282-11284	in	_
58-5	11285-11291	Figure	_
58-6	11292-11293	1	_
58-7	11294-11300	showed	_
58-8	11301-11304	the	_
58-9	11305-11312	highest	_
58-10	11313-11324	correlation	_
58-11	11325-11329	with	_
58-12	11330-11335	Smith	_
58-13	11336-11338	's	_
58-14	11339-11342	DMN	_
58-15	11343-11344	(	_
58-16	11345-11346	r	_
58-17	11347-11348	=	_
58-18	11349-11355	0.6048	_
58-19	11356-11357	)	_
58-20	11358-11359	,	_
58-21	11360-11374	frontoparietal	_
58-22	11375-11376	(	_
58-23	11377-11382	R‐CEN	_
58-24	11383-11384	:	_
58-25	11385-11386	r	_
58-26	11387-11388	=	_
58-27	11389-11395	0.6961	_
58-28	11396-11397	;	_
58-29	11398-11403	L‐CEN	_
58-30	11404-11405	:	_
58-31	11406-11407	r	_
58-32	11408-11409	=	_
58-33	11410-11415	0.782	_
58-34	11416-11417	)	_
58-35	11418-11419	,	_
58-36	11420-11423	and	_
58-37	11424-11433	executive	_
58-38	11434-11441	control	_
58-39	11442-11450	networks	_
58-40	11451-11452	(	_
58-41	11453-11454	r	_
58-42	11455-11456	=	_
58-43	11457-11463	0.6983	_
58-44	11464-11465	)	_
58-45	11466-11467	.	_

59-1	11468-11470	To	_
59-2	11471-11479	estimate	_
59-3	11480-11497	group‐differences	_
59-4	11498-11500	in	_
59-5	11501-11513	connectivity	_
59-6	11514-11520	within	_
59-7	11521-11524	the	_
59-8	11525-11533	networks	_
59-9	11534-11536	of	_
59-10	11537-11545	interest	_
59-11	11546-11547	,	_
59-12	11548-11551	FSL	_
59-13	11552-11554	's	_
59-14	11555-11559	dual	_
59-15	11560-11570	regression	_
59-16	11571-11579	analysis	_
59-17	11580-11583	was	_
59-18	11584-11593	performed	_
59-19	11594-11595	(	_
59-20	11596-11604	Beckmann	_
59-21	11605-11606	,	_
59-22	11607-11613	Mackay	_
59-23	11614-11615	,	_
59-24	11616-11625	Filippini	_
59-25	11626-11627	,	_
59-26	11628-11629	&	_
59-27	11630-11635	Smith	_
59-28	11636-11637	,	_
59-29	11638-11642	2009	_
59-30	11643-11644	;	_
59-31	11645-11654	Nickerson	_
59-32	11655-11656	,	_
59-33	11657-11662	Smith	_
59-34	11663-11664	,	_
59-35	11665-11670	Öngür	_
59-36	11671-11672	,	_
59-37	11673-11674	&	_
59-38	11675-11683	Beckmann	_
59-39	11684-11685	,	_
59-40	11686-11690	2017	_
59-41	11691-11692	)	_
59-42	11693-11694	.	_

60-1	11695-11697	In	_
60-2	11698-11703	short	_
60-3	11704-11705	,	_
60-4	11706-11710	this	_
60-5	11711-11719	approach	_
60-6	11720-11725	takes	_
60-7	11726-11729	the	_
60-8	11730-11739	estimated	_
60-9	11740-11745	group	_
60-10	11746-11750	RSNs	_
60-11	11751-11759	computed	_
60-12	11760-11763	via	_
60-13	11764-11772	meta‐ICA	_
60-14	11773-11776	and	_
60-15	11777-11784	creates	_
60-16	11785-11799	single‐subject	_
60-17	11800-11815	representations	_
60-18	11816-11818	of	_
60-19	11819-11822	the	_
60-20	11823-11830	spatial	_
60-21	11831-11841	components	_
60-22	11842-11843	.	_

61-1	11844-11849	These	_
61-2	11850-11860	components	_
61-3	11861-11864	can	_
61-4	11865-11869	then	_
61-5	11870-11872	be	_
61-6	11873-11879	tested	_
61-7	11880-11883	for	_
61-8	11884-11889	group	_
61-9	11890-11901	differences	_
61-10	11902-11907	using	_
61-11	11908-11919	permutation	_
61-12	11920-11925	tests	_
61-13	11926-11927	.	_

62-1	11928-11930	To	_
62-2	11931-11935	test	_
62-3	11936-11939	our	_
62-4	11940-11950	hypotheses	_
62-5	11951-11952	,	_
62-6	11953-11955	we	_
62-7	11956-11965	performed	_
62-8	11966-11969	the	_
62-9	11970-11979	following	_
62-10	11980-11987	planned	_
62-11	11988-11999	comparisons	_
62-12	12000-12001	:	_
62-13	12002-12010	GHB‐Coma	_
62-14	12011-12017	versus	_
62-15	12018-12035	GHB‐NoComa/No‐GHB	_
62-16	12036-12037	(	_
62-17	12038-12044	effect	_
62-18	12045-12047	of	_
62-19	12048-12056	multiple	_
62-20	12057-12068	GHB‐induced	_
62-21	12069-12074	comas	_
62-22	12075-12076	)	_
62-23	12077-12080	and	_
62-24	12081-12091	GHB‐NoComa	_
62-25	12092-12098	versus	_
62-26	12099-12105	No‐GHB	_
62-27	12106-12107	(	_
62-28	12108-12114	effect	_
62-29	12115-12117	of	_
62-30	12118-12125	GHB‐use	_
62-31	12126-12129	per	_
62-32	12130-12132	se	_
62-33	12133-12134	)	_
62-34	12135-12136	.	_

63-1	12137-12140	The	_
63-2	12141-12150	randomize	_
63-3	12151-12155	tool	_
63-4	12156-12160	from	_
63-5	12161-12164	FSL	_
63-6	12165-12169	with	_
63-7	12170-12176	10,000	_
63-8	12177-12189	permutations	_
63-9	12190-12193	and	_
63-10	12194-12211	family‐wise‐error	_
63-11	12212-12213	(	_
63-12	12214-12217	FWE	_
63-13	12218-12219	;	_
63-14	12220-12221	p	_
63-15	12222-12223	<	_
63-16	12224-12228	0.05	_
63-17	12229-12230	)	_
63-18	12231-12241	correction	_
63-19	12242-12247	using	_
63-20	12248-12251	the	_
63-21	12252-12266	threshold‐free	_
63-22	12267-12274	cluster	_
63-23	12275-12286	enhancement	_
63-24	12287-12295	followed	_
63-25	12296-12298	by	_
63-26	12299-12309	Bonferroni	_
63-27	12310-12320	correction	_
63-28	12321-12327	across	_
63-29	12328-12336	networks	_
63-30	12337-12341	were	_
63-31	12342-12346	used	_
63-32	12347-12348	(	_
63-33	12349-12354	Smith	_
63-34	12355-12356	&	_
63-35	12357-12364	Nichols	_
63-36	12365-12366	,	_
63-37	12367-12371	2009	_
63-38	12372-12373	)	_
63-39	12374-12375	.	_

64-1	12376-12386	Covariates	_
64-2	12387-12389	of	_
64-3	12390-12401	no‐interest	_
64-4	12402-12406	were	_
64-5	12407-12417	introduced	_
64-6	12418-12420	to	_
64-7	12421-12428	control	_
64-8	12429-12432	for	_
64-9	12433-12449	premorbid‐verbal	_
64-10	12450-12452	IQ	_
64-11	12453-12454	,	_
64-12	12455-12463	exposure	_
64-13	12464-12466	to	_
64-14	12467-12479	recreational	_
64-15	12480-12485	drugs	_
64-16	12486-12491	other	_
64-17	12492-12496	than	_
64-18	12497-12500	GHB	_
64-19	12501-12502	(	_
64-20	12503-12510	cocaine	_
64-21	12511-12512	,	_
64-22	12513-12523	stimulants	_
64-23	12524-12529	other	_
64-24	12530-12534	than	_
64-25	12535-12542	cocaine	_
64-26	12543-12544	,	_
64-27	12545-12552	ecstasy	_
64-28	12553-12554	,	_
64-29	12555-12558	and	_
64-30	12559-12568	sedatives	_
64-31	12569-12570	)	_
64-32	12571-12572	,	_
64-33	12573-12576	and	_
64-34	12577-12579	GM	_
64-35	12580-12586	volume	_
64-36	12587-12588	(	_
64-37	12589-12591	IQ	_
64-38	12592-12595	and	_
64-39	12596-12598	GM	_
64-40	12599-12609	introduced	_
64-41	12610-12612	as	_
64-42	12613-12619	linear	_
64-43	12620-12629	variables	_
64-44	12630-12631	;	_
64-45	12632-12640	exposure	_
64-46	12641-12643	to	_
64-47	12644-12647	the	_
64-48	12648-12658	referenced	_
64-49	12659-12664	drugs	_
64-50	12665-12667	as	_
64-51	12668-12672	five	_
64-52	12673-12678	dummy	_
64-53	12679-12688	variables	_
64-54	12689-12690	)	_
64-55	12691-12692	(	_
64-56	12693-12698	Oakes	_
64-57	12699-12701	et	_
64-58	12702-12705	al.	_
64-59	12706-12707	,	_
64-60	12708-12712	2007	_
64-61	12713-12714	)	_
64-62	12715-12716	.	_

65-1	12717-12720	The	_
65-2	12721-12729	analysis	_
65-3	12730-12733	was	_
65-4	12734-12742	repeated	_
65-5	12743-12750	without	_
65-6	12751-12754	the	_
65-7	12755-12758	use	_
65-8	12759-12761	of	_
65-9	12762-12765	the	_
65-10	12766-12768	GM	_
65-11	12769-12778	covariate	_
65-12	12779-12780	.	_

66-1	12781-12796	Between‐network	_
66-2	12797-12809	connectivity	_
66-3	12810-12818	analysis	_
66-4	12819-12822	was	_
66-5	12823-12832	performed	_
66-6	12833-12838	using	_
66-7	12839-12846	FSLNets	_
66-8	12847-12851	tool	_
66-9	12852-12853	(	_
66-10	12854-12861	version	_
66-11	12862-12865	0.6	_
66-12	12866-12867	,	_
66-13	12868-12873	https	_
66-14	12874-12875	:	_
66-15	12876-12890	//fsl.fmrib.ox	_
66-16	12891-12892	.	_

67-1	12893-12918	ac.uk/fsl/fslwiki/FSLNets	_
67-2	12919-12920	)	_
67-3	12921-12922	.	_

68-1	12923-12926	For	_
68-2	12927-12930	our	_
68-3	12931-12935	four	_
68-4	12936-12940	RSNs	_
68-5	12941-12943	of	_
68-6	12944-12952	interest	_
68-7	12953-12954	,	_
68-8	12955-12962	Pearson	_
68-9	12963-12974	correlation	_
68-10	12975-12978	and	_
68-11	12979-12986	partial	_
68-12	12987-12998	correlation	_
68-13	12999-13011	coefficients	_
68-14	13012-13016	were	_
68-15	13017-13027	calculated	_
68-16	13028-13029	,	_
68-17	13030-13033	and	_
68-18	13034-13040	Fisher	_
68-19	13041-13047	r‐to‐z	_
68-20	13048-13059	transformed	_
68-21	13060-13061	.	_

69-1	13062-13067	Group	_
69-2	13068-13079	comparisons	_
69-3	13080-13085	using	_
69-4	13086-13089	the	_
69-5	13090-13094	same	_
69-6	13095-13104	contrasts	_
69-7	13105-13107	as	_
69-8	13108-13110	in	_
69-9	13111-13114	the	_
69-10	13115-13121	within	_
69-11	13122-13129	network	_
69-12	13130-13138	analysis	_
69-13	13139-13143	were	_
69-14	13144-13153	performed	_
69-15	13154-13159	using	_
69-16	13160-13166	10,000	_
69-17	13167-13177	randomized	_
69-18	13178-13190	permutations	_
69-19	13191-13192	.	_

70-1	13193-13200	Results	_
70-2	13201-13205	were	_
70-3	13206-13219	FWE‐corrected	_
70-4	13220-13221	(	_
70-5	13222-13223	p	_
70-6	13224-13225	<	_
70-7	13226-13230	0.05	_
70-8	13231-13232	;	_
70-9	13233-13240	Winkler	_
70-10	13241-13242	,	_
70-11	13243-13250	Ridgway	_
70-12	13251-13252	,	_
70-13	13253-13260	Webster	_
70-14	13261-13262	,	_
70-15	13263-13268	Smith	_
70-16	13269-13270	,	_
70-17	13271-13272	&	_
70-18	13273-13280	Nichols	_
70-19	13281-13282	,	_
70-20	13283-13287	2014	_
70-21	13288-13289	)	_
70-22	13290-13291	.	_

